AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24377647 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loop electrosurgical excision procedure (LEEP)
Number of subjects: 314
Study 24377647 — intervention group
Group type: COMPARATOR
Intervention: Directed biopsies (3-step group)
Number of subjects: 314
Study 22546623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 132
Study 22546623 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol 25 mg/day
Number of subjects: 132
Study 22546623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 132
Study 22546623 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 132
Study 18635707 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 12
Study 18635707 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release d-amphetamine sulphate 20 mg
Number of subjects: 12
Study 18635707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17488143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (phosphodiesterase-5 inhibitor)
Number of subjects: 0
Study 17488143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injections of alprostadil (with or without papaverine and phentolamine)
Number of subjects: 0
Study 17488143 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile prostheses implantation
Number of subjects: 0
Study 15145093 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611
Study 15145093 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 611
Study 15145093 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 611
Study 11435337 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent dual-chamber cardiac pacing (DDD pacemaker with rate-drop response function)
Number of subjects: 93
Study 11435337 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker atenolol (100 mg once a day)
Number of subjects: 93
Study 9579813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 221
Study 9579813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 8117122 — intervention group
Group type: EXPERIMENTAL
Intervention: Curosurf (natural porcine surfactant)
Number of subjects: 73
Study 8117122 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (synthetic surfactant)
Number of subjects: 73
Study 8117122 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial static Crs >= 1.8 ml/cm H2O/m)
Number of subjects: 73
Study 2841724 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2‐mepivacaine 1%
Number of subjects: 26
Study 2841724 — intervention group
Group type: COMPARATOR
Intervention: mepivacaine HCl 1%
Number of subjects: 26
Study 31111882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional scalpel gingivectomy
Number of subjects: 60
Study 31111882 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted gingivectomy
Number of subjects: 60
Study 31111882 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment (Control Group)
Number of subjects: 60
Study 31111882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (TGs)
Number of subjects: 60
Study 31292176 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheters (PICCs)
Number of subjects: 42
Study 31292176 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously tunnelled central catheters (Hickman‐type devices)
Number of subjects: 42
Study 31292176 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally implantable chest wall ports (Ports)
Number of subjects: 42
Study 28035541 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA plus leflflunomide and methotrexate (30 g/d)
Number of subjects: 159
Study 28035541 — intervention group
Group type: COMPARATOR
Intervention: Control group (leflflunomide and methotrexate)
Number of subjects: 159
Study 26285109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (500 mg)
Number of subjects: 38
Study 26285109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg, on demand)
Number of subjects: 38
Study 26285109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23839902 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g daily of n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 5835
Study 23839902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5835
Study 23839902 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA levels
Number of subjects: 5835
Study 21463170 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychoanalytic treatment
Number of subjects: 20
Study 21463170 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 19304891 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat oral immediate‐release solution
Number of subjects: 0
Study 19304891 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the proximal small bowel via Enterion capsule
Number of subjects: 0
Study 19304891 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the distal small bowel via Enterion capsule
Number of subjects: 0
Study 19304891 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg bevirimat solution delivered to the colon via Enterion capsule
Number of subjects: 0
Study 17176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors (coxibs)
Number of subjects: 88116
Study 17176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, rofecoxib, etoricoxib, lumiracoxib
Number of subjects: 88116
Study 17176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 88116
Study 17176361 — intervention group
Group type: COMPARATOR
Intervention: Coxibs
Number of subjects: 88116
Study 17176361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88116
Study 17176361 — intervention group
Group type: COMPARATOR
Intervention: Non-selective NSAIDs
Number of subjects: 88116
Study 15247569 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming with a carbon‐fiber electric heating blanket (Group 1)
Number of subjects: 100
Study 15247569 — intervention group
Group type: COMPARATOR
Intervention: Passive warming with a woolen blanket (Group 2)
Number of subjects: 100
Study 10329884 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper position
Number of subjects: 49
Study 10329884 — intervention group
Group type: COMPARATOR
Intervention: Lower position
Number of subjects: 49
Study 8698959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy focusing on interpersonal and developmental vulnerabilities
Number of subjects: 30
Study 8698959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy with a developmental focus
Number of subjects: 30
Study 1725198 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 10
Study 1725198 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg b.i.d.)
Number of subjects: 10
Study 1725198 — intervention group
Group type: COMPARATOR
Intervention: Perindopril plus placebo
Number of subjects: 10
Study 6129914 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 58
Study 6129914 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam 20 mg
Number of subjects: 58
Study 6129914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study 29481448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive fatigue task (AX continuous performance test) for 60 minutes
Number of subjects: 8
Study 29481448 — intervention group
Group type: COMPARATOR
Intervention: Watching a video on trains for 60 minutes (control condition)
Number of subjects: 8
Study 31064757 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (defined as two or more fills for a statin during the year after diagnosis)
Number of subjects: 2195
Study 31064757 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of statins (control group)
Number of subjects: 2195
Study 29743051 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT journal club format
Number of subjects: 126
Study 29743051 — intervention group
Group type: COMPARATOR
Intervention: Standard journal club format
Number of subjects: 126
Study 29743051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TREAT and Standard formats
Number of subjects: 126
Study 26726822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69
Study 26726822 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 69
Study 25304723 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells (MSCs) from adipose tissue
Number of subjects: 20
Study 25304723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (or vehicle)
Number of subjects: 20
Study 22676723 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional physical activity delivered by a physiotherapist or physiotherapy assistant
Number of subjects: 47
Study 22676723 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study 22676723 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional physical activity
Number of subjects: 47
Study 20427369 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib
Number of subjects: 140
Study 20427369 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g acetaminophen
Number of subjects: 140
Study 20427369 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg parecoxib plus 5 g acetaminophen
Number of subjects: 140
Study 20427369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 18714736 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 263
Study 15760498 — intervention group
Group type: EXPERIMENTAL
Intervention: Short limb laparoscopic Roux-en-Y gastric bypass (biliopancreatic limb = 50 cm, alimentary limb = 100 cm)
Number of subjects: 48
Study 15760498 — intervention group
Group type: COMPARATOR
Intervention: Long limb laparoscopic Roux-en-Y gastric bypass (biliopancreatic limb = 100 cm, alimentary limb = 150 cm)
Number of subjects: 48
Study 15760498 — intervention group
Group type: EXPERIMENTAL
Intervention: Short limb laparoscopic Roux-en-Y gastric bypass
Number of subjects: 48
Study 15760498 — intervention group
Group type: COMPARATOR
Intervention: Long limb laparoscopic Roux-en-Y gastric bypass
Number of subjects: 48
Study 12589613 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip flexor stretching
Number of subjects: 96
Study 12589613 — intervention group
Group type: COMPARATOR
Intervention: Shoulder abductor stretching
Number of subjects: 96
Study 10210023 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (FBM) in combination with Valproic Acid (VPA)
Number of subjects: 13
Study 10210023 — intervention group
Group type: COMPARATOR
Intervention: Valproic Acid (VPA)
Number of subjects: 13
Study 8733090 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy
Number of subjects: 63
Study 8733090 — intervention group
Group type: COMPARATOR
Intervention: Cardiac surgery
Number of subjects: 63
Study 1877476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase plus heparin
Number of subjects: 2531
Study 1877476 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 2531
Study 1877476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase plus heparin (anterior infarction subgroup)
Number of subjects: 2531
Study 1877476 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (anterior infarction subgroup)
Number of subjects: 2531
Study 1877476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase
Number of subjects: 2531
Study 1877476 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 2531
Study 6311782 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin (4 g iv 6‐hourly) plus cefotaxime (2 g iv 8‐hourly)
Number of subjects: 54
Study 6311782 — intervention group
Group type: COMPARATOR
Intervention: gentamicin (1.5 mg/kg im or iv 8‐hourly) plus cefoxitin (2 g iv 6‐hourly) with metronidazole (500 mg iv 8‐hourly) for anaerobic infections
Number of subjects: 54
Study 31025050 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PAS paradigm (iPAS)
Number of subjects: 21
Study 31025050 — intervention group
Group type: COMPARATOR
Intervention: Fixed ISI of 25 ms (PAS 25)
Number of subjects: 21
Study 31025050 — intervention group
Group type: COMPARATOR
Intervention: Fixed ISI of 22 ms (PAS 22)
Number of subjects: 21
Study 29246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment
Number of subjects: 1224
Study 29246162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk All CZP patients
Number of subjects: 1224
Study 29246162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk All CZP patients
Number of subjects: 1224
Study 27192215 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD group (n=16)
Number of subjects: 63
Study 27192215 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI group (n=22)
Number of subjects: 63
Study 27192215 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of awareness of memory deficits
Number of subjects: 63
Study 27192215 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD subjects
Number of subjects: 63
Study 27192215 — intervention group
Group type: COMPARATOR
Intervention: Clinical controls (n=25)
Number of subjects: 63
Study 24253534 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants of DPP10, NPSR1, and ADAM33
Number of subjects: 1047
Study 24253534 — intervention group
Group type: COMPARATOR
Intervention: Testing cohort (n = 545)
Number of subjects: 1047
Study 24253534 — intervention group
Group type: COMPARATOR
Intervention: Replication cohort (n = 502)
Number of subjects: 1047
Study 23006968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningdong granule (NDG)
Number of subjects: 120
Study 23006968 — intervention group
Group type: EXPERIMENTAL
Intervention: NDG + Haloperidol (Hal)
Number of subjects: 120
Study 23006968 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 23006968 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (Hal)
Number of subjects: 120
Study 19943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint model for longitudinal ordinal measurements and competing risks failure time data using a partial proportional odds model.
Number of subjects: 0
Study 19943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (MRS) as the primary outcome measure.
Number of subjects: 0
Study 19943331 — intervention group
Group type: EXPERIMENTAL
Intervention: Other ordinal outcomes such as Barthel and Glasgow scales.
Number of subjects: 0
Study 17627725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra), up to one study tablet per day for 6 months
Number of subjects: 108
Study 17627725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 15668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Music-Making (RMM) activity after a 1-hour stress induction
Number of subjects: 32
Study 15668624 — intervention group
Group type: COMPARATOR
Intervention: Resting control group
Number of subjects: 32
Study 15668624 — intervention group
Group type: COMPARATOR
Intervention: Ongoing stressor group
Number of subjects: 32
Study 12585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) combined with intrauterine insemination (IUI)
Number of subjects: 103
Study 12585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) alone
Number of subjects: 103
Study 12585141 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) alone
Number of subjects: 103
Study 12585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) and IUI (Group A)
Number of subjects: 103
Study 12585141 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhenqi Zhuanyin Decoction (ZQZYD) (Group B)
Number of subjects: 103
Study 12585141 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) (Group C)
Number of subjects: 103
Study 10517054 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child intervention
Number of subjects: 62
Study 10517054 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-only intervention
Number of subjects: 62
Study 10517054 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only intervention
Number of subjects: 62
Study 8239492 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg
Number of subjects: 430
Study 8239492 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg bid
Number of subjects: 430
Study 2905824 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 12
Study 2905824 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 12
Study 2905824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29570538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (REB) 8 mg
Number of subjects: 11
Study 29570538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 27270348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin with oxaliplatin
Number of subjects: 1729
Study 27270348 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin without oxaliplatin
Number of subjects: 1729
Study 27270348 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin with or without oxaliplatin
Number of subjects: 1729
Study 24912740 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and vibration via Buzzy
Number of subjects: 176
Study 24912740 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 176
Study 23230096 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (1.5 g daily)
Number of subjects: 304
Study 23230096 — intervention group
Group type: COMPARATOR
Intervention: glipizide (30 mg daily)
Number of subjects: 304
Study 21624418 — intervention group
Group type: COMPARATOR
Intervention: BioThrax alone
Number of subjects: 69
Study 21624418 — intervention group
Group type: COMPARATOR
Intervention: 1 mg of CPG 7909 alone
Number of subjects: 69
Study 21624418 — intervention group
Group type: EXPERIMENTAL
Intervention: BioThrax plus 1 mg of CPG 7909
Number of subjects: 69
Study 18177871 — intervention group
Group type: EXPERIMENTAL
Intervention: Myomectomy through ultraminilaparotomy
Number of subjects: 113
Study 18177871 — intervention group
Group type: COMPARATOR
Intervention: Myomectomy through laparotomy
Number of subjects: 113
Study 16394112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 166310
Study 16394112 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposed HRT
Number of subjects: 166310
Study 16394112 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed HRT
Number of subjects: 166310
Study 16394112 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT initiation at different age groups
Number of subjects: 166310
Study 16394112 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at MI event
Number of subjects: 166310
Study 14503803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens (additive)
Number of subjects: 21
Study 14503803 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens (substitutive)
Number of subjects: 21
Study 14503803 — intervention group
Group type: COMPARATOR
Intervention: Control (non-anthracycline regimens)
Number of subjects: 21
Study 10829042 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg before each radiotherapy fraction
Number of subjects: 60
Study 10829042 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine
Number of subjects: 60
Study 9603657 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic liarozole 75 mg BID for at least 2 months
Number of subjects: 7
Study 8160899 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam/Clindamycin (A/C)
Number of subjects: 73
Study 8160899 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/Clindamycin (G/C)
Number of subjects: 73
Study 3415798 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 112
Study 3415798 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracts
Number of subjects: 112
Study 3415798 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill packs
Number of subjects: 112
Study 3415798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of techniques
Number of subjects: 112
Study 3415798 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 112
Study 31873765 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (0.025-0.4 mg/kg)
Number of subjects: 100
Study 31873765 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 100
Study 29242294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 30
Study 29242294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28950888 — intervention group
Group type: EXPERIMENTAL
Intervention: Web/DVD plus booklet intervention
Number of subjects: 168
Study 28950888 — intervention group
Group type: COMPARATOR
Intervention: Booklet only (control group)
Number of subjects: 168
Study 25794218 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 107
Study 25794218 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity cement vertebroplasty (HVCV)
Number of subjects: 107
Study 23021013 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 whole eggs/day (EGG)
Number of subjects: 37
Study 23021013 — intervention group
Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study 21118743 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 200 mg single dose
Number of subjects: 42
Study 21118743 — intervention group
Group type: COMPARATOR
Intervention: Modafinil 200 mg single dose
Number of subjects: 42